The DOCK4 Knockout NCI-H1299 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population featuring targeted disruption of the human DOCK4 gene in the NCI-H1299 non-small cell lung carcinoma cell line. This heterogeneous pool of gene-edited cells provides a robust loss-of-function model system for investigating DOCK4-dependent cellular processes. The polyclonal format avoids clonal artifacts and captures the diversity of CRISPR-induced mutations, enabling functional studies without the selection pressure of single-cell cloning. Researchers can rely on this population to explore DOCK4??s roles in signal transduction, cytoskeletal dynamics, and disease-relevant phenotypes.
The NCI-H1299 host cell line is a well-characterized KRAS-mutant human lung adenocarcinoma model derived from lymph node metastasis. Its aggressive, metastatic origin makes it a biologically relevant background for studying tumor cell migration, invasion, and adhesion. The KRAS oncogenic mutation drives constitutive pro-survival and pro-migratory signals, creating a permissive context for dissecting the contribution of DOCK4 to metastatic behavior. This cell line is extensively used in cancer biology to elucidate mechanisms of non-small cell lung cancer progression and to identify therapeutic targets.
DOCK4 functions as a guanine nucleotide exchange factor (GEF) that specifically activates the small GTPase RAC1 by catalyzing GDP-to-GTP exchange. Within the signaling network, DOCK4 forms a complex with adaptor proteins ELMO1/2 and responds to upstream inputs from integrin signaling and the EPHB2 receptor, with regulatory crosstalk from PI3K and SRC kinase. Once activated, RAC1-GTP engages effectors including PAK kinases, leading to phosphorylation cascades involving LIMK and cofilin, and ultimately promotes actin polymerization through the ARP2/3 complex. This pathway orchestrates dynamic remodeling of the actin cytoskeleton, focal adhesion turnover, and lamellipodia formation, thereby driving cell migration and invasion. DOCK4 also interfaces with CRK and RHOG, linking it to broader Rho GTPase signaling networks.
In the KRAS-mutant NCI-H1299 context, DOCK4 knockout provides a powerful tool to delineate RAC1-centric pathways that cooperate with oncogenic KRAS to drive metastatic dissemination. Disruption of DOCK4 can reveal dependencies on RAC1-mediated actin dynamics for tumor cell motility and invasiveness, offering insight into how Ephrin and integrin signals are transduced in metastatic lung cancer cells. This model is particularly valuable for assessing the relative contribution of DOCK4-ELMO-RAC1 signaling versus alternative GEF pathways, and for evaluating therapeutic strategies aimed at blocking RAC1-dependent metastasis.
Typical applications include Transwell migration/invasion assays, wound healing assays, and Rac1 activity measurements using G-LISA to quantify GTP-bound RAC1. Researchers can perform western blotting for phospho-PAK as a downstream readout, immunofluorescence for F-actin to visualize cytoskeletal reorganization, and co-immunoprecipitation to confirm DOCK4-ELMO complex integrity. This knockout cell model also supports siRNA/shRNA rescue experiments to validate specificity and cell adhesion assays to examine attachment properties. Beyond cancer, DOCK4??s link to neurodevelopmental disorders such as autism spectrum disorder and intellectual disability makes these cells useful for exploring neuronal cell biology in a lung cancer-derived background. For further technical details or custom inquiries, please contact Ascent Research.
